EAU 2018 - Prostate Specific Antigen (PSA) Response in Men With Nonmetastatic Castration-Resistant Prostate Cancer (M0 CRPC) Treated With Enzalutamide: Results From PROSPER

Copenhagen, Denmark (UroToday.com) M0 CRPC or nmCRPC is an area of unmet need. Development of metastases is associated with increasing baseline PSA and PSA doubling time <10 months. 2-3  Median metastasis-free survival (MFS) was 25-30 months in the placebo arms of several randomized controlled trials.1-3  Delaying time to all metastases is clinically relevant, with potential to delay cancer-related morbidity and prolong overall survival (OS). Enzalutimide significantly improved OS and radiographic progression-free survival (rPFS) in men with chemotherapy-naive M1 CRPC in the phase 3 PREVAIL study. 5 Enzalutimide was superior to bicalutamide in improving rPFS in the subgroup of patients with chemotherapy-naive M0 CRPC in the phase 2 STRIVE study. 6 We hypothesized that enzalutimide will delay metastases development in men with M0 CRPC and rapidly rising PSA (PSA doubling time 2265≤ 10 months). 

Poster Sternberg PROSPER PSA EAU2018 030918aClick Image to Enlarge


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.